China Universal Asset Management Co. Ltd. Grows Stake in DexCom, Inc. (NASDAQ:DXCM)

China Universal Asset Management Co. Ltd. increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 24.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,580 shares of the medical device company’s stock after buying an additional 1,274 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in DexCom were worth $512,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. raised its holdings in shares of DexCom by 4.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after acquiring an additional 162 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares during the last quarter. Riverview Trust Co raised its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares during the last quarter. Finally, Koa Wealth Management LLC grew its stake in DexCom by 7.7% in the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after buying an additional 270 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DXCM shares. Canaccord Genuity Group raised their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Leerink Partners cut their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Trading Down 0.9 %

DXCM opened at $86.83 on Monday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business has a 50 day simple moving average of $80.77 and a two-hundred day simple moving average of $76.21. The firm has a market capitalization of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.